Biotech: Time to buy the dip?

This month's 11 percent drop in the iShares Nasdaq Biotechnology ETF has investors worried if the "biotech bubble" is bursting. But is it too soon to give up on a sector that's up 250 percent in the last five years?

One biotech CEO isn't worried about the pressure on the sector. Acceleron's Dr. John Knopf said on Thursday's edition of CNBC's "Fast Money," "We just like to focus on our products and develop our products."

"The clinical folks like the data and so do the medical community, and we expect to present more data this June," he added.

Check out what Acceleron has coming down the pipeline in "Fast Money's" interview with the founder & CEO of Acceleron.

Contact Fast Money

  • Showtimes

    Halftime Report - Weekdays 12p ET
    Fast Money - Weekdays 5p ET

Halftime Report

  • Bill Nygren, Oakmark Fund, explains why Apache, Bank of America and Google will be winners in 2015.

  • Nick Tiller, Sustainable America founder and chairman, tells CNBC's Kate Kelly oil prices are poised for a tradable rally. Tiller likes the Brent ETF and energy sector.

  • Discussing interesting trends contributing to the market's rally into year's end, with the FMHR trader Josh Brown and Dan Greenhaus, BTIG.